retatrutide phase 3 results Today, we announced new data from the latest study of retatrutide, an investigational triple hormone receptor agonist being studied for adults living with obesity or overweight with at least… GLP-1 Survey: 37.5% of Dose:2.50 mg Promotes Metabolic Flexibility

retatrutide phase 3 results Today, we announced new data from the latest study of retatrutide, an investigational triple hormone receptor agonist being studied for adults living with obesity or overweight with at least… GLP-1 Survey: 37.5% of Dose:2.50 mg Promotes Metabolic Flexibility

GLP-1 Survey: 37.5% of People Stop GLP-1s after Just 3 Months - Renew Bariatrics

He framed their compounding as a response to Novo Nordisk’s anticompetitive tactics

Promotes Metabolic Flexibility

Dose:2.50 mg

Gallbladder problems have also been observed in some people taking these medications—and specific GLP-1 agonists ( like Ozempic® and Wegovy® ) have their own side effect profiles